Proton Pump Inhibitors: The Culprit for Barrett's Esophagus?

Overview

Journal Front Oncol

Specialty Oncology

Date 2015 Jan 27

PMID 25621278

Citations 9

Authors

Omran Alsalahi

Anca D Dobrian

Affiliations

Soon will be listed here.

Citing Articles

Pathogenesis of pepsin-induced gastroesophageal reflux disease with advanced diagnostic tools and therapeutic implications.

Li C, Cao X, Wang H Front Med (Lausanne). 2025; 12:1516335.

PMID: 40046936 PMC: 11880273. DOI: 10.3389/fmed.2025.1516335.

sp. Facilitate the Repair of DNA Damage Caused by Bile-Induced Reactive Oxygen Species in Experimental Models of Gastroesophageal Reflux Disease.

Bernard J, Chinnaiyan V, Almeda J, Catala-Valentin A, Andl C Antioxidants (Basel). 2023; 12(7).

PMID: 37507854 PMC: 10376144. DOI: 10.3390/antiox12071314.

Topical Alginate Protection against Pepsin-Mediated Esophageal Damage: E-Cadherin Proteolysis and Matrix Metalloproteinase Induction.

Samuels T, Blaine-Sauer S, Yan K, Plehhova K, Coyle C, Johnston N Int J Mol Sci. 2023; 24(9).

PMID: 37175640 PMC: 10178445. DOI: 10.3390/ijms24097932.

The Protease Inhibitor Amprenavir Protects against Pepsin-Induced Esophageal Epithelial Barrier Disruption and Cancer-Associated Changes.

Blaine-Sauer S, Samuels T, Yan K, Johnston N Int J Mol Sci. 2023; 24(7).

PMID: 37047737 PMC: 10095080. DOI: 10.3390/ijms24076765.

Effects of proton pump inhibitor use on the esophageal microbial community.

Tasnim S, Miller A, Jupiter D, Hamilton C, Reep G, Krill T BMC Gastroenterol. 2020; 20(1):312.

PMID: 32967615 PMC: 7513526. DOI: 10.1186/s12876-020-01460-3.

References

Zhao J, Gregersen H . Relationships of CDXs and apical sodium-dependent bile acid transporter in Barrett's esophagus. World J Gastroenterol. 2013; 19(18):2736-9. PMC: 3653147. DOI: 10.3748/wjg.v19.i18.2736. View

Fischbach L, Graham D, Kramer J, Rugge M, Verstovsek G, Parente P . Association between Helicobacter pylori and Barrett's esophagus: a case-control study. Am J Gastroenterol. 2014; 109(3):357-68. PMC: 4046944. DOI: 10.1038/ajg.2013.443. View

Pohl H, Welch H . The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J Natl Cancer Inst. 2005; 97(2):142-6. DOI: 10.1093/jnci/dji024. View

Wang K, Sampliner R . Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol. 2008; 103(3):788-97. DOI: 10.1111/j.1572-0241.2008.01835.x. View

Gilbert E, Luna R, Harrison V, Hunter J . Barrett's esophagus: a review of the literature. J Gastrointest Surg. 2011; 15(5):708-18. DOI: 10.1007/s11605-011-1485-y. View

Hvid-Jensen F, Pedersen L, Funch-Jensen P, Drewes A . Proton pump inhibitor use may not prevent high-grade dysplasia and oesophageal adenocarcinoma in Barrett's oesophagus: a nationwide study of 9883 patients. Aliment Pharmacol Ther. 2014; 39(9):984-91. DOI: 10.1111/apt.12693. View

Spechler S, Sharma P, Traxler B, Levine D, Falk G . Gastric and esophageal pH in patients with Barrett's esophagus treated with three esomeprazole dosages: a randomized, double-blind, crossover trial. Am J Gastroenterol. 2006; 101(9):1964-71. DOI: 10.1111/j.1572-0241.2006.00661.x. View

Castell D, Kahrilas P, Richter J, Vakil N, Johnson D, Zuckerman S . Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis. Am J Gastroenterol. 2002; 97(3):575-83. DOI: 10.1111/j.1572-0241.2002.05532.x. View

Kastelein F, Spaander M, Biermann K, Steyerberg E, Kuipers E, Bruno M . Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus. Gastroenterology. 2011; 141(6):2000-8. DOI: 10.1053/j.gastro.2011.08.036. View

10.

Barnett K, Bell C, McKnight W, Dicay M, Sharkey K, Wallace J . Role of cyclooxygenase-2 in modulating gastric acid secretion in the normal and inflamed rat stomach. Am J Physiol Gastrointest Liver Physiol. 2000; 279(6):G1292-7. DOI: 10.1152/ajpgi.2000.279.6.G1292. View

11.

Wu A, Crabtree J, Bernstein L, Hawtin P, Cockburn M, Tseng C . Role of Helicobacter pylori CagA+ strains and risk of adenocarcinoma of the stomach and esophagus. Int J Cancer. 2003; 103(6):815-21. DOI: 10.1002/ijc.10887. View

12.

Heath E, Canto M, Piantadosi S, Montgomery E, Weinstein W, Herman J . Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J Natl Cancer Inst. 2007; 99(7):545-57. PMC: 3755596. DOI: 10.1093/jnci/djk112. View

13.

Ridlon J, Kang D, Hylemon P . Bile salt biotransformations by human intestinal bacteria. J Lipid Res. 2005; 47(2):241-59. DOI: 10.1194/jlr.R500013-JLR200. View

14.

Huang J, Zheng G, Sumanac K, Irvine E, Hunt R . Meta-analysis of the relationship between cagA seropositivity and gastric cancer. Gastroenterology. 2004; 125(6):1636-44. DOI: 10.1053/j.gastro.2003.08.033. View

15.

Chow W, Blaser M, Blot W, Gammon M, Vaughan T, Risch H . An inverse relation between cagA+ strains of Helicobacter pylori infection and risk of esophageal and gastric cardia adenocarcinoma. Cancer Res. 1998; 58(4):588-90. View

16.

Nasr A, Dillon M, Conlon S, Downey P, Chen G, Ireland A . Acid suppression increases rates of Barrett's esophagus and esophageal injury in the presence of duodenal reflux. Surgery. 2011; 151(3):382-90. DOI: 10.1016/j.surg.2011.08.021. View

17.

Rudolph R, Vaughan T, Storer B, Haggitt R, Rabinovitch P, Levine D . Effect of segment length on risk for neoplastic progression in patients with Barrett esophagus. Ann Intern Med. 2000; 132(8):612-20. DOI: 10.7326/0003-4819-132-8-200004180-00003. View

18.

Omer Z, Ananthakrishnan A, Nattinger K, Cole E, Lin J, Kong C . Aspirin protects against Barrett's esophagus in a multivariate logistic regression analysis. Clin Gastroenterol Hepatol. 2012; 10(7):722-7. PMC: 3435144. DOI: 10.1016/j.cgh.2012.02.031. View

19.

Hofmann A, MYSELS K . Bile acid solubility and precipitation in vitro and in vivo: the role of conjugation, pH, and Ca2+ ions. J Lipid Res. 1992; 33(5):617-26. View

20.

McQuaid K, Laine L, Fennerty M, Souza R, Spechler S . Systematic review: the role of bile acids in the pathogenesis of gastro-oesophageal reflux disease and related neoplasia. Aliment Pharmacol Ther. 2011; 34(2):146-65. DOI: 10.1111/j.1365-2036.2011.04709.x. View